Cover Image

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis

In clinical practice, interruption of treatment may not result in immediate cessation of disease control, and some patients even experience sustained treatment response following treatment interruption. This post hoc analysis of UNCOVER-1 and -2 Phase 3 clinical trials characterized the time to loss...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kim Papp (Author), Carle Paul (Author), C. Elise Kleyn (Author), Yu-Huei Huang (Author), Tsen-Fang Tsai (Author), Christopher Schuster (Author), Celine El Baou (Author), Agoston Toth (Author), Elisabeth Riedl (Author), Ulrich Mrowietz (Author)
Format:	Book
Published:	Medical Journals Sweden, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
by: Alexander Egeberg, et al.
Published: (2022)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study
by: Yang Lo, et al.
Published: (2021)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
by: Kristian Reich, et al.
Published: (2022)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
by: Saxon D. Smith, et al.
Published: (2023)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
by: April Armstrong, et al.
Published: (2019)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020)

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016-2021
by: Adam Reich, et al.
Published: (2023)

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
by: Lluís Puig, et al.
Published: (2020)

Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis
by: Rui Yuan Xia, et al.
Published: (2023)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
by: Sara Ghoneim, et al.
Published: (2017)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
by: Matteo Megna, MD, et al.
Published: (2023)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017)

Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
by: Bucur S, et al.
Published: (2024)

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019)

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
by: Gil Yosipovitch, et al.
Published: (2018)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
by: Andrea Chiricozzi, et al.
Published: (2023)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023)

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024)

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis
by: Jacob P. Thyssen, et al.
Published: (2023)

Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
by: Ting-Shun Wang, et al.
Published: (2013)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
by: Craig Leonardi, et al.
Published: (2020)

Patient's perception and importance of clear/almost clear skin in moderate-to-severe plaque psoriasis: Results of clear about psoriasis survey in Taiwan
by: Yu-Huei Huang, et al.
Published: (2019)

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region
by: Annunziata Dattola, et al.
Published: (2024)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
by: Martina Burlando, et al.
Published: (2022)

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
by: Annunziata Raimondo, MD, et al.
Published: (2021)

Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study
by: Ying Li, et al.
Published: (2024)

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
by: April W. Armstrong, et al.
Published: (2024)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
by: April W. Armstrong, et al.
Published: (2024)

Monocyte to high-density lipoprotein cholesterol ratio decreased in patients with psoriasis treated with ixekizumab
by: Funda Tamer, et al.
Published: (2023)

Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
by: Elisabeth Riedl, et al.
Published: (2024)